BCL2L1 and neoplasm: By comparing the tumor response (Vfinal/Vinitial) at D10 in Alb-R26Met treated versus non-treated (NT) mice, we observed that either treatment with Decitabine or MEK+BCL-XL inhibitors already stopped tumor growth or led to their regression as compared with NT tumors (Figure 3C, right).